Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept in Wet AMD with Good Baseline Vision
NCT06330220Phase 4Completed
- Sponsor
- Seoul National University Hospital
- Start
- Feb 2021
- Primary completion
- Feb 2022
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in exudative macular degeneration, sponsored by Seoul National University Hospital. Started Feb 2021; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT06330220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06330220.